AFT Pharmaceuticals Limited (ASX:AFP)

Market Cap	314.63M +19.1%
Revenue (ttm)	207.12M +19.0%
Net Income	15.30M +50.3%
EPS	0.14 +59.1%
Shares Out	n/a
PE Ratio	20.57
Forward PE	23.76
Dividend	0.02 (0.52%)
Ex-Dividend Date	Jun 18, 2025

Volume	3,870
Average Volume	1,942
Open	3.190
Previous Close	2.980
Day's Range	2.980 - 3.190
52-Week Range	2.200 - 3.370
Beta	0.43
RSI	43.06
Earnings Date	Feb 18, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AFP

Financial Performance

In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.

Financial numbers in NZD